OCX - Indikator likuiditas cepet oncocyte.com

The biopharmaceutical business of OncoCyte Corporation (OCX) relies on a steady demand for medications, although sanctions could disrupt component supplies. Diagnostic accuracy depends on the prompt transportation of samples in thermal boxes. The price evolution of OncoCyte Corporation (OCX) on the GURU.Markets platform is currently at 3.84. Meanwhile, the development of transplantation tests requires scaling up to achieve full self-sufficiency.

OncoCyte Corp. (OCX) - Rasio cepet saka 04.07.2022 nganti 18.06.2025

OCX (oncocyte.com): rincian analitis lan laporan miturut indikator

- nilai pasar lan prakiraan target analis:

Bagan rega OncoCyte Corp.|OCX - Konsensus nilai wajar

- statistik kapitalisasi pasar:

Biji pasar OncoCyte Corp.|OCX - Nilai Dipunlarasaken Utang lan Kas

- indikator kapitalisasi buku:

Nilai Buku saben Saham OncoCyte|OCX - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku oncocyte.com|OCX - Total Aset Bisnis

- rincian struktur utang lan likuiditas bisnis:

- indikator bathi lan kelipatan valuasi:

OCX - Asil keuangan resik

Pambiji fundamental:OncoCyte Corp., OCX

Short-term solvency assessment is critical for capital-intensive companies. This quick ratio measures the ability of OncoCyte Corporation (OCX) to settle obligations using its most liquid assets, completely excluding slow-moving inventories. The quick ratio trend reveals a risk of excessive capital freezing. For a biopharmaceutical business operating within strict FDA frameworks, such a check confirms financial stability while adhering to rigorous medical regulations.

Analisis perusahaan pesaing